2 results match your criteria: "Heart Institute (INCOR) and the Medical School Hospital[Affiliation]"
Use of combined chemotherapy with etoposide and methotrexate, both associated to lipid nanoemulsions for atherosclerosis treatment in cholesterol-fed rabbits.
Cardiovasc Drugs Ther
February 2015
Lipid Metabolism Laboratory, Heart Institute (INCOR) and the Medical School Hospital, São Paulo, Av. Dr. Eneas C. Aguiar 44, 1 subsolo, São Paulo, SP, CEP 0543000, Brazil.
Purpose: Treatment of atherosclerotic rabbits with intravenous methotrexate or etoposide carried in lipid nanoemulsions (LDE) markedly reduced the lesions in the aorta. Here, the combined treatment with LDE-methotrexate and LDE-etoposide was investigated aiming to increase the anti-atherosclerosis effect.
Methods: Thirty-six male rabbits received a diet with 1 % cholesterol for 2 months.
Anti-atherogenic effects of methotrexate carried by a lipid nanoemulsion that binds to LDL receptors in cholesterol-fed rabbits.
Cardiovasc Drugs Ther
December 2013
Lipid Metabolism Laboratory of the Heart Institute (INCOR) and the Medical School Hospital, São Paulo, SP, Brazil.
Purpose: Nanoemulsions (LDE) with a lipid composition resembling that of LDL can concentrate in aortic lesions and when associated with anti-blastic agents, such as paclitaxel or etoposide, decrease atherosclerotic lesions induced in rabbits. Our aim was to test the association of a lipophilic derivative of methotrexate, didodecyl-methotrexate (ddMTX) to LDE on the lesions and on the expression of pro-inflammatory and anti-inflammatory genes.
Methods: Twenty male New Zealand rabbits were fed 1 % cholesterol diet for 60 days.